Pharmaceutical Drug Delivery Market - Emerging Trends to Boost the Global Revenue


Posted March 24, 2022 by mmvaidya

To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.
 
According to the new market research report, "Pharmaceutical Drug Delivery Market by Route of Administration (Oral, Injectors, Implantable, Syrups, Gels, Pulmonary, Solutions, Tablets, Syringes), Application (Cancer, Diabetes), Facility of Use (Hospitals), COVID-19 Impact - Global Forecast to 2026", The global pharmaceutical drug delivery market is projected to reach USD 2,206.5 billion by 2026 from USD 1,656.9 billion in 2021, at a CAGR of 5.9% during the forecast period.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1085

Global Industry Growth Boosting Factors:

Growth in the pharmaceutical drug delivery market can largely be attributed to factors such as the rising prevalence of chronic diseases, growing biologics market, increasing R&D investments, and technological advancements & new product launches.

Overview:

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Driver: Growth in biologics market

Recognizing the potential for biologics manufacturing, companies, such as Evonik (Germany), have made several strategic developments. For instance, the company increased its production capacity by acquiring SurModics in 2021, which focuses on controlled-release parenteral applications. In addition, Evonik acquired complementary technologies, such as Boehringer Ingelheim’s RESOMER platform, to improve its capability in this market. Similarly, in 2019, WuXi Biologics announced the launch of WuXi Vaccines, a joint venture with Shanghai Hile Bio-Technology Co., Ltd. The companies entered into the strategic partnership under which WuXi Vaccines will build a dedicated facility and supply a commercial product for the global market. The biopharmaceutical industry has witnessed the emergence of a new class of therapeutics, showing significant potential in new treatments in oncology, diabetes, and other disease areas.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=1085

Restraint: Risk of needlestick injuries

Needlestick injuries are one of the most serious health and safety threats:

# According to PharmaJet, in the US, around 600,000 to 800,000 needlestick injuries are reported every year.
# The Occupational Safety and Health Administration (OSHA) estimates that around 5.6 million workers in the US are at the risk of exposure to blood-borne pathogens due to needlestick injuries.
# Furthermore, the CDC estimates that an average of 385,000 needlestick injuries occur annually in US hospital settings.
# Similarly, in Europe, more than 1 million needlestick injuries are reported each year (Source: Becton, Dickinson and Company).

Opportunity: Self-administration and home care

Self-administration and home care are expected to provide significant growth opportunities for players operating in the pharmaceutical drug delivery market. This is mainly due to the rising geriatric population, as elderly individuals form a large consumer base for drug delivery devices for home care. This factor is also increasing the need for application-specific injection, inhalation, topical, and transdermal drug products that are designed to cater to the needs of caregivers and patients.

Challenge : Pricing pressure

Government bodies in both developed and developing countries are encouraging cost-saving measures, such as cutting drug reimbursement prices and promoting the greater use of generics. Drug manufacturers across the globe are facing significant cost reduction pressures from government bodies, insurers, and patients. This downward pricing pressure is resulting in the greater uptake of drugs in emerging markets where the demand for low-cost therapeutics is high. However, this is affecting the profitability of several pharmaceutical companies. This trend is expected to continue in the coming years owing to the continuous pressure for reducing pharmaceutical prices by insurers, pharmacy benefit managers (PBMs), and public and private payers due to concerns about covering more new medicines to treat prevalent conditions, such as high cholesterol and diabetes.

Speak to Analyst for More Detailed Information@ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=1085
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Makarand Vaidya
Country United States
Categories Industry , Medical , News
Tags pharmaceutical drug delivery , pharmaceutical drug delivery market
Last Updated March 24, 2022